We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AGL Angle Plc

0.25 (2.00%)
Last Updated: 11:43:57
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Angle Plc AGL London Ordinary Share
  Price Change Price Change % Share Price Last Trade
0.25 2.00% 12.75 11:43:57
Open Price Low Price High Price Close Price Previous Close
12.50 12.25 12.75 12.50
more quote information »
Industry Sector

Angle AGL Dividends History

No dividends issued between 15 Apr 2014 and 15 Apr 2024

Top Dividend Posts

Top Posts
Posted at 22/3/2024 09:30 by 5oletrader
Re BBC article/grail/ctDNA. Some 'stuff' to ponder?-Is the Galleri test FDA approved?• The Galleri test has NOT been cleared OR approved by the FDA.Https://• In the US, because Galleri has NOT yet won approval from the FDA, it is NOT covered by US government health insurance schemes.-NHS-Galleri trial:• 'IF' the Galleri test does NOT WORK well in this setting, then we will still have learned important information about what research needs to be done in the FUTURE to improve cancer screening.Https:// results and next steps:• Once the results of the trial are available, these will be shared publicly. Often this is in a science journal, press release, or on the trial website. Results are likely to be ready in 2026 but may take LONGER. Https://,test%20works%20in%20the%20NHS.-Interesting Article:• Not everyone is convinced the tests live up to the hype. Several health experts and scientists told the Financial Times that the tests could harm rather than help some patients due to risks associated with misdiagnosis, over-diagnosis and over-treatment.• Susan Bewley, a consultant obstetrician and emeritus professor of obstetric and women's health at King's College London, says the problem with MCED screening is that the MORE of this you DO on HEALTHY people the MORE ERRORs you get.• "This sort of screening test could bankrupt the NHS, prioritise people who are well over those who are sick, and make people ill. This is ethically dubious," says Bewley. "Before these tests are rolled out we need to follow hundreds of thousands of people over many years to determine if the treatments actually stop them from dying."• Bewley is concerned that the way the NHS trial is structured means that Grail is likely to claim success even though many of the people with early-stage cancer may never have become ill.Https:// me cynic - how did the 'NHS gig' come about in the first place?• Illumina and Grail increased their US lobbying spending fivefold to $14.6M• ?Illumina also expanded lobbying in Europe and the UK, where it hired former prime minister David Cameron as an adviser in 2019 shortly before winning a gene sequencing contract with a company owned by the Department of Health and Social Care.• ?In November 2020, the NHS struck its deal with Grail to pilot Galleri - a collaboration that is key to winning regulatory approval. -Why mention above? Well:• Parsortix is FDA approved.• AGL achieved breakthrough CTC & ctDNA clinical results (same blood sample.)• Assay development underway.• AN mentioned at year end providing tests FOR patients not just ABOUT. AGL to be major competition for MEDC test providers? -• Remember when Illumina bought Grail back for $8bn (deal blocked). 'PIE in the SKY'I leave you with:• The BILLION DOLLAR QUESTION - What' is AGL worth?
Posted at 19/3/2024 23:27 by 5oletrader
With just...• One Business - AGL Lab ServicesWith just...• One Customer - EISAIWith just...• One FDA approval - BREASTEquates to just...• One $451+M *OPPORTUNITY*-NOTE - Eisai has several ongoing trials with a number of investigational compounds and biological agents in various stages of development.-To AGL this equates to:• 40,090 total patients• $3,750 per blood sample• 3 x time points (per patient)-40,090 x $3,750 = $150+MMultiply x 3 time points = $451+M-Opportunity (1)• A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/?Metastatic Breast Cancer• NCT0457229572 x patients-Opportunity (2)• Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer• NCT0456890233 x patients -Opportunity (3)• A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer• NCT06188559135 x patients -Opportunity (4)• A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer• NCT0428808936 x patients-Opportunity (5)• A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer• NCT0262397222 x patients-Opportunity (6)• Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer (AIRE)• NCT0503376982 x patients-Opportunity (7)• Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer (HERMIONE-10)• NCT05302778200 x patients -Opportunity (8)• Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/?HER2- Breast Cancer, Post Progression on Al + CDK4/?6 Inhibitor• NCT05181033120 x patients-Opportunity (9)• Detect V /? CHEVENDO (Chemo vs. Endo)• NCT02344472270 x patients-Opportunity (10)• Southeast Netherlands Advanced Metastatic Breast Cancer Registry (SONABRE)• NCT035771976000 x patients -Opportunity (11)• Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008 (ESME-MBC)• NCT0327531133000 x patients-Opportunity (12)• Scalp Cooling in MBC• NCT04986579120 x patients-Https:// above with other large pharma companies and...AGL has the opportunity to be a BILLION DOLLAR company?!-Keep talking it down!ATB
Posted at 11/3/2024 08:32 by radderssandy
Hi Digger, I sent an email to IG (with help from another poster) towards the end of January. I also attended the Shares presentation in February and had a good chat with IG afterwards.

As a LTH, I know AGL’s timelines can slip and it is frustrating. But I respect IG. He sent me a thorough & considered reply to my email (and it covered a number of topics) and I liked his lack of BS responses to my questions when I spoke to him.

I asked him about the Solaris/prostate study.

To summarise (Feb 2024)
There is regular and ongoing dialogue between AGL & Solaris. Solaris understand the need for the work that is being undertaken and want the best results from the samples.

The first part of the patient enrolment is done, which is the 100 samples (as per the Interim results).

IG emphasised that these samples are “precious̶1;, AGL are currently optimising the molecular solution and how they are most effectively going to analyse these samples.

They think prostate will get better results with RNA than DNA.

IG said they anticipate the results coming out in H2.

I said to IG that timelines have slipped and pushed it as far as I could do. It would appear that the company have “re-calibrated” their timelines to the Interim results and have rather airbrushed out any previous guidance. The company line is, that in the Interims, they promised headline results by the year end, which they achieved with the BiDetect announcement. To help improve adoption by the industry of CTC’s they prioritised these BiDetect results.

I think there is some ambiguity in the Interim’s presentation, I definitely understood it as being prostate & ovarian. But reading back the results RNS it is unspecific “Headline results from the Company's major clinical studies expected by the year end demonstrating key clinical applications of the Parsortix system for patient care”. The wording had changed in the November business update to “the first of which we expect to publish before the year end.” Which was the BiDetect.

It will be interesting to see what the Prelim results say on the progress made. I don’t doubt that the results will be good, it’s just they prioritised BiDetect and most things with AGL, unfortunately, are slower than anticipated.
Posted at 08/3/2024 10:39 by spa362
I agree. In fact AGL is no different from any other company at this stage of its cycle. The point here is that AGL has the advantage of a unique patented technology and FDA approval. ON that basis I am very happy to be a long term holder and am confident that commercial gains will follow - and that AGL will either grow considerably or (more likely) be bought out by a bigger fish at some point in the cycle. On the basis, the current valuation is far too low. Significant gains to come here for those that are prepared to be patient - far more likely than not...inevitably, there will be a price-moving RNS at some point
Posted at 30/1/2024 13:04 by 5oletrader
If anyone is interested? (For Context)-PROSTATE CANCER:• The Urology Group has a news story here - at 1m32s to 1m37s "I DO HAVE ABIT OF FAITH NOW THAT THERE IS THE NEXT THING COMING ALONG" - make of that what you will? How about AGLs CTC based liquid biopsy which potentially offers a unique opportunity to triage men with elevated PSA?•• Reenforcing the significance of AGLs partnership with MidLantic Urology - (part of the above Urology Group)•• The Urology Group is an affiliate of Solaris Health.• CURRENT SCREENING:• In the United States, the Preventive Services Task Force recommends that all men between the ages of 55-69 years be offered annual prostate screening using a blood-based prostate specific antigen (PSA) test.• PROCESS FLAWED?:• While prostate cancer mortality rates have declined since the advent of PSA testing, it is UNCERTAIN what proportion of this is due to PSA screening.• The best available evidence from randomized trials found that screening has at most a small benefit in reducing prostate cancer mortality. SCREENING has NO BENEFIT in REDUCING overall MORTALITY.• OPPORTUNITY:• Dr Jose Moreno, Principal Investigator, MidLantic Urology, commented:• "Even though PSA is a valuable marker of response to prostate cancer treatment, its role in screening is modest at best and can lead to both overdiagnosis of clinically indolent prostate cancer and underdiagnosis of clinically significant prostate cancer which can result in increased rates of local failure and metastatic disease.• ANGLE's Parsortix platform has the potential to enable molecular characterisation of the cancer using a blood test in patients undergoing both traditional ultrasound biopsies and MRI fusion biopsies. The preliminary data suggest that we may be able to create an assay for the detection of clinically significant prostate cancer that has high specificity and sensitivity. Moreover, the assay can be customized to operate in a wide spectrum of prostate cancer disease states, including pre-prostate biopsy, after a negative biopsy, active surveillance, after local failure, and in early and late metastatic disease states. If our results are validated, our MidLantic Urology patients and Solaris Health affiliates may be the first to benefit from these developments."-NEW DRUG ON THE BLOCK:• Novartis - Pluvicto•• Patient Monitoring? Another commercial opportunity for AGL to chase?-ATB
Posted at 28/1/2024 09:10 by bones699
So let's talk about financial fundamentals here shall we rather than day dreaming chasing vanishing rainbows over the horizon. 🌈 🤔.

Now Parsortix has been cleared for nearly two years and there is around 24 main cancer types of which only one has been approved by the FDA for testing breast cancer using the Parsortix machine.

So here is the conundrum not only has AGL generated virtually no sales revenues in two years despite having approval for breast cancer treatment but to generate sales it is unwilling to complete the testing required for the remaining 23 cancer types expecting the third party labs to do this themselves.

Well it doesn't take a rocket scientist to figure out that to date LabCorp and Quest Diagnostics the two USA leading lab company's has shown next to no interest in buying Parsortix machines due no doubt to the severe limitation in cancer testing.

Hence Newlands claim at the recent Investor Meet that third party labs are likely to take on Parsortix and seek their own accreditation because that is exactly what he was alluding too appear unfounded!

As to date non of the big USA lab chains have done what Newland claimed they would do in nearly two years since FDA clearance!...

We can now see that the financial fundamentals are beginning to fall apart, low cash balances c.£12m at best, a high monthly cash burn rate over £1.4m and Newland claiming that an additional £6m revenues will occur out of apparently thin air only reference at the Investor Meet by their CFO looking quite twitcher I might add when asked about the cash runway was funding would be from 'strategic opportunities' and 'project milestones' whatever that was meant to mean before alluding to tapping the market as in the past, just gave the game away don't you think!

So there we have the crux of the matter a business running out of both time and money before the next eventual cash raise.

Meanwhile the market has now cottoned on to Newlands tricks ramping RNS releases all of which lack financials and timelines with the seeming sole objective to keep the share price up ahead of a potential cash raise to mitigate the size and scale of yet another damaging £20m share issuance, to chuck onto the pile of burnt investor cash over £130m to date, and at what share price 12p or much less by the look of things..

Meanwhile other competitors are entering the market space and closer to full FDA approval than AGL while 'BIG PHARMA' could have picked AGL up for under 10p and show no interest, no surprises there then!

AGL should carry a government health warning that these 🌈's are never free and can and do fade over time!
Posted at 17/1/2024 20:22 by 5oletrader
Anyone else find the ref to EISAI interesting? • 80 ACTIVE oncology trials• 60,000 Participants• 3 potential Timelines for SAMPLING patient blood (before, during, after)• AGL state sliding scale charge for processing blood samples - range from £1k to £5k (say average at £3k ?)AM I RIGHT WITH THIS???• 180,000 samples x £3k sample charge = £540M of potential opportunity for AGL with just ONE large Pharma customer? -Re Distributors:• Good to see 100+ boots on the ground - fully trained staff (establishing global presence)• Nicely Incentivised at 30% commission re sales-HOCKEY STICK revenue referenced once again with:• 2024 revenues expected to AT LEAST treble.-Re the Parsortix Machine itself:• Easy to Use• One (1) of AGLs technicians is capable of running twenty (20) machines simultaneously - impressive?-Re ILLUMINA:• generating $4B in sequencing revenues• approx 3000 illumina systems in current use• Financially - Plugin the 'Parsortix Inside' technology with above - fruitful partnership?-Re Ovarian:• AGL currently using in house molecular platform• Want to MOVE it across to Illumina and ThermoFisher systems. WHY?-Re DDR Inhibitors Summit:• AGL attending• DDR inhibitor development is evolving rapidly, marked by the continuous emergence of new targets. ASTRAZENECA and MERCK reaffirm their commitment to DDR inhibitors, yet more pharmaceutical companies like ROCHE and GILEAD are diving into this therapeutic strategy; biotech companies like ARTIOS and IDEAYA remain dedicated todelivering safe and effective treatments to patients.•• Note ARTIOS - AGL already involved with them •"Opportunity Knocks"-ATB
Posted at 15/1/2024 20:55 by 5oletrader
Re AGL Contract announcement with Eisai Inc. Again pondering the significance? ADCs:-The antibody-drug conjugate (ADC) market is picking up right where it left off in 2023 as ROCHE has made a potential $1 BILLION deal with China-based MediLink Therapeutics to develop a next-generation ADC in oncology.,Epidermal%20Growth%20Factor%20Receptor%203.What I found interesting:• ROCHE will be solely responsible for developing and commercializing the treatment globally.-What I found more interesting.• If I run the name Joseph Eid (as MrK alluded to) I notice this.• His previous experience includes senior positions in CLINICAL DEVELOPMENT and medical affairs at Bristol Myers Squibb, Merck & Co. and Hoffman-La ROCHE. above ROCHE deal. MediLink will work with Roche's China Innovation Center to push the candidate into Phase I clinical trials.• Phase I trials - still a lot of work still be done.A way in with Mr Eid? Could AGL assist? Thought - it highlights the kind of money involved. It's a multi BILLION dollar industry. With only 14 ADCs approved by FDA for clinical use and MORE than 100 ADCs in clinical trial - AGL have large open opportunities to tout for business (all in the ADC space alone).,solid%20tumors%20(Table%201).-Food for thought?
Posted at 15/1/2024 17:34 by 5oletrader
@MrK - Welcome back! (hope things went as well as they could - under the circumstances). You are clearly respected/valued here - your post 22445 evidences that.If there are any Charitable Causes you feel strongly about - feel free to highlight them here. STAY STRONG! (From those that don't know you from Adam).-Re STUDY you posted - Thanks for highlighting potential patient monitoring timeframes. few things that caught my eye also:• Re ref to CELLSEARCH PLATFORM - Isolates CTCs based on EpCAM expression and will therefore MISS CTCs that have UNDERGONE epithelial-to-mesenchymal transition (EMT). This LIMITATION EXPLAINS WHY some STUDIES have FAILED to CORRELATE CTCs with oncological OUTCOMES in prostate cancer.• Re ref to PARSORTIX PLATFORM - The epitope-independent PARSORTIX CTC isolation system relies on cell size and deformability to detect CTCs, ALLOWING ISOLATION of CTCs ACROSS the EMT SPECTRUM.• We hypothesise that detection of CTCs by the PARSORTIX SYSTEM is an ACCURATE INDICATOR of micro-metastasis and in COMBINATION with CTC GENE EXPRESSION may PREDICT FUTURE METASTASIS development.• SOME bashed you re study time frame. However maybe they missed the significance of the study? To PREDICT Radical Prostatectomy TREATMENT FAILURE. This will change Healthcare as we know it! re your post 22149 I WAS going to use your guesstimated value on Lab Service Charge by AGL (1500 dollars say 1200 quid) to carryout CTC and ctDNA analysis. HOWEVER I see @TIMBO003 highlighted in his post 22683 that opportunities had increased (in particular sample testing, where they can now generate revenue of up to $5K/sample). SO I will meet you both in the middle - and go with 3250 dollars per sample (say 2550 quid)?Above study requires 294 patients with samples taken at:• Screening/Baseline•Pre-Op• Post-Op 3 months• Post-Op 6 months •• Post-Op 12 months• Follow Up Annually 2 to 10 years• Screen/Baseline - 294 patients x 2550 quid = 749,700 quid• Pre-Op - 294 patients x 2550 quid = 749,700 quid• Post-Op 3 months 294 patients x 2550 quid = 749,700 quid• Post-Op 6 moths - 294 patients x 2550 quid = 749,700 quid• Post-Op 12 Months - 294 patients x 2550 quid = 749,700 quid• TOTAL for 12 MONTHS = 3,748,500 quid YEARLY x 10 years = 37,485,000 quid.I probably butchered that - BUT the point I am trying to make - this is just ONE EXAMPLE of what AGLs LAB SERVICEs can generate.NOW factor in what @MIA alluded to in post 22149 - APPLY ABOVE and THINK Pharma Drug Trials, Other cancer trails to predict treatment failure - Breast, Ovarian, Lung etc and you have a solid BUSINESS CASE for AGL LABs? (referencing lab services only here - not including products business).•(Above study is funded by the Prostate Cancer UK & Movember Major Awards in Curative Treatment Grant 2020 (MA-CT20-011)).*jr5ibz*_up*MQ..*_ga*OTExNDk1NDgzLjE3MDUzMzQ2MTM.*_ga_1SBQYXCVE6*MTcwNTMzNDYxMi4xLjAuMTcwNTMzNDYxMi4wLjAuMA..&gclid=EAIaIQobChMIm8yDu-LfgwMVI4tQBh3UvgtGEAAYASAAEgI1WvD_BwE-@TIMOO003 - re your comment 22686 - Work conducted with Illumina, now being repeated with Thermo-fisher. Good to see AGL are actively engaged with two (2) of the six (6) Key Companies in this space: •Agilent Technologies•FHoffman-La-Roche (to be ticked?)•Guardant Health•Illumina (tick) •QIAGEN •Thermo Fisher Scientific (tick)This report is worth a read. Global Liquid Biopsy Market - Outlook & Forecast 2023-2028 - I note your post 22721 - I made some observations in post 22407. Purely speculative but interesting.-As for this disinformation about Parsortix and its usage. Lets put the record straight on that. The Parsortix PC1 system is an In Vitro Diagnostic Device:•In vitro diagnostics (IVD) are TESTS done on SAMPLES such as BLOOD or tissue that have been taken from the human body. In vitro diagnostics can detect diseases or other conditions, and can be used to monitor a person’s overall health to help cure, treat, or prevent diseases. •In vitro diagnostics may also be USED in PRECISION MEDICINE to IDENTIFY PATIENTS who are LIKELY to BENEFIT from SPECIFIC treatments or therapies. These in vitro diagnostics can include next generation sequencing tests, which scan a person’s DNA to detect genomic variations. -Standby for drowning of post. -ATB
Posted at 05/1/2024 12:04 by 5oletrader
Quibble til the cows come home - I remain focussed on the ultimate goal here - PRECISION MEDICINE!-Collaborative/partnership working is the future for AGL. To build something - it's done brick by brick.-The words - Genomics, Transcriptomics, and Proteomics were thrown at us by AN in the EISAI RNS. -•GENOMICs is the large-scale study of all of the DNA that makes up a given organism or system.•TRANSCRIPTOMICs is the study of the complete set of RNA produced by the genome of a given organism or population of cells.•PROTEOMICs is the large-scale study of a set of proteins that are produced and/or modified in a given organism or system.•From the RNS "The use of CTC biomarkers in clinical trials is a RAPIDLY GROWING FIELD"-The introduction of next generation sequencing (NGS) for DNA sequencing has SIGNIFICANTLY ACCELERATED the study of GENOMICs, allowing for many discoveries that are ADVANCING science and human health. This is particularly true with the ADVENT of PRECISION MEDICINE.-I previously highlighted the increased investment coming to the sector and government support. The NHS quote "Our vision is that the power of genomics in predicting, preventing and diagnosing disease, and targeting treatment is accessible to all as part of routine care in the NHS"."Our ambition over the NEXT FIVE YEARs is to ACCELERATE embedding the USE of GENOMIC MEDICINE across the NHS, providing a world leading, equitable service to populations and individuals". some still question AGLs ability to add value to this market? Think:•Drug development•Drug trails on patients•Patients Monitoring (before and after drug approval).-Tie yesterday's RNS with all the above and it all makes sense. Dr Karen Miller nailed it "We are particularly excited about finding such high levels of ADDITIONAL VARIENTs in the CTCs that are NOT present in ctDNA, as this provides potentially additional information for the clinicians on which to BASE their TREATMENT OPTIONs."-I also liked point number five (5). As well as the unique insight provided by DNA analysis of the CTCs harvested by the Parsortix system, the CTC sample offers the potential to EXTEND the ANALYSIS from DNA to RNA, protein, and morphological analysis of CTCs and CTC clusters, all of which together make the intact living cancer cell (CTC) the best sample for repeat non-invasive testing to DRIVE PERSONALISED CARE for cancer patients.-I am pleased to see long standing/knowledgeable AGL holders stand firm on a BB that has once again become saturated with garbage.-ATB

Your Recent History

Delayed Upgrade Clock